Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2008

View Archived Issues

Labopharm reports positive results for phase III trazodone study

e-STAR data show risperidone long-acting injection beneficial in schizophrenia

Add-on pimavanserin improves efficacy and safety of risperidone in schizophrenia

Cervical cancer vaccine safe, immunogenic in stage IB and IIA patients

Pro-Pharmaceuticals reports encouraging data from phase II trial of Davanat in colorectal cancer

Blood pressure control safely achieved with clevidipine in high risk patients

AstraZeneca submits application for Seroquel and Seroquel XR in the E.U.

Keryx Biopharmaceuticals completes phase III clinical trial of Sulonex

La Jolla Pharmaceutical presents an update on the phase III trial of Riquent for SLE

Recent patents impart novel treatment options for cancer

Washington University investigators study role of moss protein in Alzheimer's disease

Targanta submits NDA to FDA for oritavancin

Preliminary clinical data show significant HIV viral load reduction with IDX-899

Silodosin NDA accepted for filing by FDA for benign prostatic hyperplasia

Biovitrum completes exploratory phase II study of BVT-28949 in glaucoma

Positive efficacy data reported from phase II Gabapentin GR trial

SCH-532706 safe and well tolerated in combination with ritonavir

Valeant reports positive phase III results for retigabine in RESTORE 1

Decapeptyl 6-month formulation shows similar efficacy to 3-month triptorelin

Study shows self-applied diarrhea vaccine patch has robust immune response

Recent Merck patents describe novel agents for sleep disorders

Recent Allergan patents disclose new therapeutics for glaucoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.